Alphapharm Pty Limited v Wyeth [2009] FCA 945

Alphapharm Pty Limited v Wyeth [2009] FCA 945

Wyeth established a reasonably strong prima facie case that Alphapharm's intended supply of Enlafax-XR would infringe claims 4 and 27 of its method patent and would suffer irreparable harm not adequately compensable by damages if an injunction were refused. Although Alphapharm established a prima facie case for invalidity on certain grounds, these were insufficient, in the balance of convenience, to deprive Wyeth of interim protection. Therefore, interlocutory injunctions restraining Alphapharm from infringement were appropriate.

Parties
Applicant/cross Respondent: Alphapharm Pty Limited; First Respondent/first Cross Claimant: Wyeth; Second Respondent/second Cross Claimant: Wyeth Australia Pty Limited
Jurisdiction
Australia
Judgment Date
25 August 2009
Procedural Posture
Interlocutory Application in Patent Litigation / Decision on Application for Interlocutory Injunction
Outcome
Interlocutory relief granted
Legal Topics
Interlocutory Injunctions, Patent Infringement, Patent Validity, Balance of Convenience
Intellectual Property Patents Interlocutory Injunctions Patent Infringement Patent Validity Balance of Convenience

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 6 Authorities cited 28 Party arguments 2 Amounts and remedies 5
Sign in to unlock

Parties

Alphapharm Pty Limited

Applicant/cross Respondent

Wyeth

First Respondent/first Cross Claimant

Wyeth Australia Pty Limited

Second Respondent/second Cross Claimant

Procedural Posture

Interlocutory Application in Patent Litigation / Decision on Application for Interlocutory Injunction

Legal Issues

  1. 1 Proper approach to the grant/refusal of interlocutory injunction where patentee alleges infringement and alleged infringer asserts invalidity
  2. 2 Whether Wyeth established a prima facie case of infringement by Alphapharm's intended actions
  3. 3 Whether Alphapharm established a prima facie case that the patent is invalid (fair basis, false suggestion, manner of manufacture, inventive step, sufficiency)

Ratio Decidendi

Wyeth established a reasonably strong prima facie case that Alphapharm's intended supply of Enlafax-XR would infringe claims 4 and 27 of its method patent and would suffer irreparable harm not adequately compensable by damages if an injunction were refused. Although Alphapharm established a prima facie case for invalidity on certain grounds, these were insufficient, in the balance of convenience, to deprive Wyeth of interim protection. Therefore, interlocutory injunctions restraining Alphapharm from infringement were appropriate.

Court Disposition

Interlocutory relief granted

Orders

  • Alphapharm restrained from infringing claims 4 and 27 (insofar as claim 27 is dependent on claim 4) of Australian Patent No 2003259586, including by importing, marketing, selling, supplying, or offering Enlafax-XR or any product comprising the same generic modified release formulation of venlafaxine hydrochloride...
  • Alphapharm restrained from applying to list Enlafax-XR Products on the Schedule of Pharmaceutical Benefits.